Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mannkind Corp (NQ: MNKD )

7.070 +0.050 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mannkind Corp

< Previous 1 2 3 4 5 6 Next >
MannKind Earnings Preview
Via Benzinga
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
From MannKind
Via GlobeNewswire
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
From MannKind
Via GlobeNewswire
MannKind's Return On Capital Employed Overview
Via Benzinga
MannKind Corporation (MNKD) Q3 2022 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2022. 
Via The Motley Fool
MannKind: Q2 Earnings Insights
  MannKind (NASDAQ:MNKD) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
From MannKind
Via GlobeNewswire
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
From MannKind
Via GlobeNewswire
3 Biotech Stocks Under $15 Worth a Second Look in 2023
All three stocks have promising therapies that could drive revenue in the coming years. 
Via The Motley Fool
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
From MannKind
Via GlobeNewswire
MannKind To Rally 57%? Here Are 5 Other Price Target Changes For Wednesday
Via Benzinga
Tyson Foods To $61? Plus Needham Slashes PT On This Stock By 33%
  B of A Securities cut the price target on Tyson Foods, Inc. (NYSE: TSN) from $73 to $61. Tyson Foods shares fell 1.9% to $66.44 in pre-market trading. 
Via Benzinga
MannKind Corporation Reports 2022 Third Quarter Financial Results
Conference Call to Begin Today at 9:00 a.m. (ET) 
From MannKind
Via GlobeNewswire
Earnings Preview: MannKind
MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that MannKind will... 
Via Benzinga
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
From MannKind
Via GlobeNewswire
7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up
While these market ideas are risky, they offer enough relevance to be intriguing. 
Via InvestorPlace
7 Penny Stocks That Actually Have a Buy Rating
Penny stocks are always a risky proposition. However, investors can still find penny stocks with buy ratings right now. 
Via InvestorPlace
MannKind Shares Fall After Completing Initial Stage Lung Disease Study
MannKind Corporation (NASDAQ: MNKD) has successfully completed a Phase 1 study of clofazimine inhalation suspension (MNKD 101), an inhalation treatment option for nontuberculous mycobacterial (NTM)... 
Via Benzinga
Earnings Outlook For MannKind
  MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that MannKind will... 
Via Benzinga
Jim Cramer Recommends Selling This Stock: 'No One Ever Likes Me To Say Anything Bad' About This Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canoo Inc. (NASDAQ: GOEV) is losing money. "We’re done with those stocks that just lose money," he added. 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
MannKind Earnings Preview
MannKind (NASDAQ:MNKD) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that MannKind will... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
3 Market ETF Stocks to Buy This Week on Fed Jitters
The bears have two major tailwinds and the Fed is one. Here are 3 ETF stocks to buy into a potential relief rally after the event blows over. 
Via InvestorPlace
4 Penny Stocks Insiders Are Buying: MannKind, Crexendo And More
Russian unemployment rate rose to a five-month high of 4.4% in January from 4.3% in the prior month. Investors, meanwhile, focused on some notable ... 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday. Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 39.2% to... 
Via Benzinga
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday. Nordstrom, Inc. (NYSE: JWN) shares jumped 38.7% to $27.11 after the company reported... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.